140130-20-7

Upstream product

• 14077-58-8 ethoxyacetyl chloride 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 

Downstream Products

• 140130-21-8 (S)-4-Benzyl-3-{(2S,3R)-2-ethoxy-3-hydroxy-3-[2-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-benzofuran-5-yl]-propionyl}-oxazolidin-2-one 
• 702697-65-2 tert-butyl N-{4'-[3-(4-benzyl-2-oxooxazolidin-3-yl)-2-ethoxy-1-hydroxy-3-oxo-propyl]biphenyl-3-ylmethyl}-N-methylcarbamate 
• 817618-02-3 N-(4-{4-[3-(4(S)-benzyl-2-oxooxazolidin-3-yl)-2(S)-ethoxy-1(S)-hydroxy-3-oxopropyl]phenyl}thiophen-2-ylmethyl)-N-methyloctanoylamide 
• 817618-06-7 N-(5-{4-[3-(4(S)-benzyl-2-oxooxazolidin-3-yl)-2(S)-ethoxy-1(S)-hydroxy-3-oxopropyl]phenyl}thiophen-2-ylmethyl)-N-methyloctanoylamide 
• 668477-24-5 (S)-4-benzyl-3-[(2S,3R)-3-(4-benzyloxy-2-methyl-phenyl)-2-ethoxy-3-hydroxy-propionyl]-oxazolidin-2-one 
• 668477-53-0 (S)-4-benzyl-3-[(2S,3R)-3-(4-benzyloxy-2-ethyl-phenyl)-2-ethoxy-3-hydroxy-propionyl]-oxazolidin-2-one 
• 1160811-33-5 C₃₅H₃₄N₂O₇S 
• 1160811-36-8 C₃₆H₃₃F₃N₂O₇S 
• 1160811-38-0 C₄₁H₃₈N₂O₇S 
• 398150-04-4 N-{4'-[(1R,2S)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-ethoxy-1-hydroxy-3-oxopropyl]biphenyl-3-ylmethyl}-N-methylbenzamide 
• 475482-04-3 (S)-4-benzyl-3-((2S,3R)-3-{3,5-dimethyl-4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2-ethoxy-3-hydroxy-propionyl)-oxazolidin-2-one 
• 475482-06-5 (S)-4-benzyl-3-((2S,3R)-2-ethoxy-3-hydroxy-3-{3-methoxy-4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionyl)-oxazolidin-2-one 
• 475482-03-2 (S)-4-benzyl-3-((2S,3R)-2-ethoxy-3-hydroxy-3-{3-methyl-4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionyl)-oxazolidin-2-one 
• 140130-22-9 5-{(S)-2-Ethoxy-3-[(S)-4-benzyl-2-oxo-3-oxazolidinyl]-3-oxopropyl}-2-[(5-methyl-2-phenyl-4-oxazolyl)methyl]benzofuran 

Relevant academic research and scientific papers

NOVEL COMPOUNDS THAT MODULATE PPARγ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

The invention relates to novel compounds corresponding to the general formula (I) below: (I) and also to the method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism),-or alternatively in cosmetic compositions.

Non-thiazolidinedione antihyperglycaemic agents. Part 5: Asymmetric aldol synthesis of (S)-(-)-2-oxy-3-arylpropanoic acids

Boron-mediated asymmetric aldol reactions of substituted benzaldehyde 5 with 2-oxyethanoyloxazolidinones 4a-e, containing electron withdrawing, chelating, and bulky alkoxy and aryloxy groups, gave variable yields of syn- aldol adducts 6a-e in high diastereoisomeric excess. Dehydroxylation of these adducts afforded 7a-e in a sequence which complements the traditional Evans asymmetric alkylation strategy. Cleavage of the auxiliary from 7a-e afforded antihyperglycaemic (S)-(-)-2-oxy-3-arylpropanoic acids 3a-e in excellent enantiomeric excess.

Hypoglycemic activity of a series of α-alkylthio and α-alkoxy carboxylic acids related to ciglitazone

The thiazolidinedione moiety of ciglitazone and its analogues can be replaced by an α-alkoxy or α-thioether carboxylic acid group. The influence of the nature of the R group, the length of the connector to the aromatic backbone of the molecule, and the stereochemistry have been studied. The most potent compounds have glucose-lowering activity at doses as low as 0.01 mg/kg.

3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives

A method of using certain 3-aryl-2-hydroxypropionic acid derivatives and analogs in the treatment of hypertension.